Gilead Sciences, Inc. (GILD) Galapagos NV, - M&A Call - Slideshow

Gilead Sciences announced a strategic M&A call in April 2026, detailing its acquisition plans involving Galapagos NV, a biotech firm specializing in inflammatory and fibrotic disease therapies. The slide deck presented during the call outlines financial and operational synergies, emphasizing pipeline integration and cost efficiencies expected from the deal. Key focus areas include Galapagos’ late-stage drug candidates, particularly in rheumatoid arthritis and idiopathic pulmonary fibrosis, aligning with Gilead’s expansion in immunology. The transaction aims to bolster Gilead’s R&D capabilities, leveraging Galapagos’ proprietary drug discovery platforms and clinical-stage assets. Investor materials highlight projected revenue growth and timeline milestones, signaling confidence in the deal’s long-term value creation for shareholders.